Biomarkers for early detection of colorectal cancer and polyps: Systematic review

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 9, 2014, Pages 1712-1728

  Shah, Reena ^a   Jones, Emma ^b   Vidart, Victoire ^c   Kuppen, Peter J K ^d   Conti, John A ^e,f   Francis, Nader K ^a,c  

^a YEOVIL DISTRICT HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GUAIAC; PLASMA PROTEIN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER SCREENING; COLORECTAL CANCER; COLORECTAL POLYP; DNA MARKER; EARLY DIAGNOSIS; HUMAN; OCCULT BLOOD; PREDICTIVE VALUE; REVIEW; SYSTEMATIC REVIEW; ANIMAL; BLOOD; COLONIC POLYPS; COLORECTAL NEOPLASMS; DOG;

ANIMALS; COLONIC POLYPS; COLORECTAL NEOPLASMS; DOGS; EARLY DETECTION OF CANCER; HUMANS; OCCULT BLOOD; TUMOR MARKERS, BIOLOGICAL;

EID: 84907172039     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0412     Document Type: Review

References (67)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008. Int J Cancer 2010; 127: 2893-917.
2. Assess Your Risk for Colorectal Cancer. [cited 2014 Feb.] Available from: http://www.fascrs.org/patients/treatments-and-screenings/assess-your-risk-for-colorectal-cancer/screening/American Society of Colon and Rectal Surgeons 2014.
3. Colorectal Cancer Survival by Stage. National Cancer Intelligent Network Data. June 2009.
4. Walsh J, Terdiman J. Colorectal cancer screening - scientific review. JAMA 2003; 289: 1288-96.
5. Bretthauer M. Colorectal cancer screening. J Intern Med 2011; 270: 87-98.
6. Vernon S. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997; 89: 1406-22.
7. Bond JH. Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am 2002; 12: 11-21.
8. Robb K, Power E, Kralj-Hans I, Edwards R, Vance M, Atkin W, et al. Flexible sigmoidoscopy screening for colorectal cancer: uptake in a population-based pilot program. J Med Screen 2010; 17: 75-8.
9. Pox CP, Altenhofen L, Brenner H, Theilmeier A, Von Stillfried D, Schmiegel W. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 2012; 142: 1460-7.
10. Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008; 359: 1207-17.
11. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007; 16: 1935-53.
12. Rawson JB, Bapat B. Epigenetic biomarkers in colorectal cancer diagnostics. Expert Rev Mol Diagn 2012; 12: 499-509.
13. Ma Y, Zhang P, Wang F, Qin H. Searching for consistently reported upand down-regulated biomarkers in colorectal cancer: a systematic review of proteomic studies. Mol Biol Rep 2012; 39: 8483-90.
14. Berger BM, Ahlquist DA. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology 2012; 44: 80-8.
15. Population Estimates. [cited 2013 Dec.] Available from: http://www.statistics.gov.uk. The office of UK National Statistics. 2013.
16. Population Age Distribution. [cited 2013 Dec.] Available from: http://www.censusscope.org. Age distribution in population. 2010.
17. Bowel Cancer Incidence. [cited 2013 Dec.] Available from: http://www.cancerresearchuk.org/cancerinfo/cancerstats/types/bowel/incidence/. Cancer Research UK. 2010.
18. Colorectal Adenoma Incidence. [cited 2013 Dec.] Available from: http://www.fascrs.org/physicians/education/core-subjects/2002/polyps/. American Society of Colon and Rectal Surgeons. 2014.
19. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
20. Zhang H, Song YC, Dang CX. Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer. Int J Med Sci 2013 10: 230-4.
21. Zhang J, Yand S, Xie Y, Chen X, Zhao Y, He D, et al. Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China. Cancer Epidemiol 2012; 36: 73-7.
22. Kalimutho M, Del Vecchio Blanco G, Cretella M, Mannisi E, Sileri P, Formosa A, et al. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection. Int J Colorectal Dis 2011; 26: 583-92.
23. Azuara D, Rodriguez-Moranta F, De Oca J, Soriano-Izquierdo A, Mora J, Guardiola J, et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer 2010; 9: 168-76.
24. Melotte V, Lentjes MH, Van Den Bosch SM, Hellebreker DM, De Hoon JP, Wouters KA, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 2009; 101: 916-27.
25. Glockner SC, Dhir M, Joo MY, McGarvey KE, Van Neste J, Louwagie J, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009; 69: 4691-9.
26. Wang DR, Tang D. Hypermethylated SFRP2 gene in fecalDNAis a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol 2008; 14: 524-31.
27. LeungWK, To KF, Man ES, Chan MY, Hui AJ, Ng SM, et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol 2007; 102: 1070-6.
28. Takai T, Kanaoka S, Yoshida KI, Hamaya Y, Ikuma M, Miura N, et al. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7mRNAassays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2009; 18: 1888-93.
29. Shastri YM, Loitsch S, Hoepffner N, Povse N, Hanisch E, Rösch W, et al. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol 2008; 103: 1496-504.
30. Mulder SA, Van Leerdam ME, Van Vuuren AJ, Francke J, Van Toorenenbergen AW, Kuipers EJ, et al. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol 2007; 19: 878-82.
31. Koss K, Maxton D, Jankowski J. Fecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumor staging and surgical intervention. Colorectal Dis 2008; 10: 244-8.
32. Haug U, Rothenbacher D, Wente N, Seiler C, Stegmaier C, Brenner H. Tumor M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs. colorectal cancer patients. Br J Cancer 2007; 96: 1329-34.
33. Shastri YM, Naumann M, Oremek GM, Hanisch E, Rösch W, Mössner J, et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer 2006; 119: 2651-56.
34. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by noninvasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol 2006; 12: 7007-11.
35. Sonoda H, Kohnoe S, Yamazato T, Satoh Y, Morizono G, Shikata K, et al. Colorectal cancer screening with odor material by canine scent detection. Gut 2011; 60: 814-9.
36. Pack SC, Kim HR, Lim SW, Kim HY, Ko JY, Lee KS, et al. Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer. Int J Colorectal Dis 2013; 28: 139-47.
37. Lange CE, Campan M, Hinoue T, Schmitz RF, Van Der Meulen de Jong AE, Slingerland H, et al. Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS ONE 2012; 7: e50266.
38. Cassinotti E, Melson J, Liggett T, Melnikov A, Yi Q, Replogle C, et al. DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer 2012; 131: 1153-7.
39. Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med 2011; 9: 133.
40. Tanzer M, Balluff B, Distler J, Hale K, Leodolter A, Rocken C, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS ONE2010; 5: e9061.
41. Lee BB, Lee EJ, Jung EH, Chun HK, ChangDK, Song SY, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 2009; 15: 6185-91.
42. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008; 54: 414-23.
43. Han M, Choong TL, Hong WZ, Chao S, Zheng R, Kok TY, et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res 2008; 14: 455-60.
44. Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Huang D, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS ONE 2012; 7: e44398.
45. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, et al. Plasma MiR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 2012; 256: 544-51.
46. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127: 118-26.
47. Ng EO, Chong WS, Jin H, Lam EY, Shin VY, Yu J, et al. Differential expression of microRNAsin plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-81.
48. Wilson S, Damery S, Stocken D, Dowswell G, Holder R, Ward ST, et al. Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test. Br J Cancer 2012; 106: 1431-8.
49. Liu C, Pan C, Shen J, Wang H, Yong L. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer. Int J Med Sci 2011; 8: 39-47.
50. Chen JS, Kuo YB, Chou YP, Chan CC, Fan CW, Chen KT, et al. Detection of autoantibodies against Rabphilin-3A-like protein as a potential biomarker in patient's sera of colorectal cancer. Clin Chim Acta 2011; 412: 1417-22.
51. Mead R, Duku M, Bhandari P, Cree IA. Circulating tumor markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer 2011; 105: 239-45.
52. Babel I, Barderas R, Diaz-Uriarte R, Moreno V, Suarez A, Fernandez- Acenero M, et al. Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol Cell Proteomics 2011; 10: M110.001784.
53. Pederson J, Blixt O, Bennett E, Tarp M, Dar I, Mandel U, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 2011; 128: 1860-71.
54. Tagi T, Matsui T, Kikuchi S, Hoshi S, Ochiai T, Kokuba Y, et al. Dermokine as a novel biomarker for early-stage colorectal cancer. J Gastroenterol 2010; 45: 1201-11.
55. Mroczko B, Groblewska M, Okulczyk B, Kedra B, Szmitkowski M. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Colorectal Dis 2010; 25: 1177-84.
56. De Chiara L, Rodriguez-Pineiro AM, Rodriguez-Berrocal FJ, Cordero OJ, Martinez-Ares D, Paez de la Cadena M. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer 2010; 10: 333.
57. Kim HJ, Kang HJ, Lee H, Lee ST, Yu MH, Kim H, et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res 2009; 8: 1368-79.
58. Fentz AK, Spori M, Spangenberg J, List HJ, Zornig C, Dorner A, et al. Detection of colorectal adenoma and cancer based on transthyretin and C3a-desArg serum levels. Proteomics Clin Appl 2007; 1: 536-44.
59. Bellows CF, Zhang Y, Chen J, Frazier ML, Kolonin MG. Circulation of progenitor cells in obese and lean colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 2011; 20: 2461-8.
60. Mori Y, Olaru A, Cheng Y, Agarwal R, Yang J, Luvsanajv D, et al. Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer 2011; 18: 465-78.
61. Lind GE, Raiborg C, Danielsen SA, Rognum TO, Thiis-Evensen E, Hoff G, et al. SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene 2011; 30: 3967-78.
62. Magnusson K, de Wit M, Brennan D, Johnson L, McGeeS, Lundberg E, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol 2011; 35: 937-48.
63. Kanojia D, Gard M, Gupta S, Gupta A, Suri A. Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol 2011; 178: 1009-20.
64. DNA stool test recommended as screening tool. Cancer Discov 2014; 4: 0F4.
65. Shrubsole M, Cai Q, Wen W, Milne G, Smalley WE, Chen Z, et al. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res 2012; 5: 336-42.
66. Dulal S, Keku T. Gut microbiome and colorectal adenomas. Cancer J 2014; 20: 225-31.
67. Kumar S, Huang J, Abbassi-Ghadi N, ͆panél P, Smith D, Hanna GB. Selected ion flow tube mass spectrometry analysis of exhaled breath for volatile organic compound profiling of esophagogastric cancer. Anal Chem 2013; 85: 6121-8.